BIIB34:BVMF
Biogen Inc BDR
R$230.10
0.00%
(0.00) 1D
Nov 4, 3:38:07 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
37.46B
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82M
No. of employees
8K
Mkt. cap
37.46B
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
4 hours ago
History Says 1 Month Has Been the S&P 500's Most Reliable Since 1950. It's Only Weeks Away.
Anadolu Ajansı
·
2 hours ago
US stock markets close midweek higher
Eurasia Business News
·
4 hours ago
Stock Market Today: Dow Jones, Nasdaq, S&P 500 Rally on November 11, 2026; Oil Rises, Gold Slips
KuCoin
·
9 hours ago
In June, Bitcoin outperformed the S&P 500 on just 1 in 5 tra
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com